Conciseness

The body is largely efficient — dense tool signatures, threshold tables, and a fallback matrix with little padding — but the 'Domain Reasoning' section explains acute-vs-chronic toxicity concepts at length, and some guidance is restated (e.g., LOOK UP DON'T GUESS versus per-phase notes). This matches 'efficient; minor instances of over-explanation that could be trimmed' rather than the fully lean anchor 5.

Actionability

Highly concrete guidance: exact tool names with parameter types ('FAERS_count_reactions_by_drug_event (drug_name: str, limit: int, default 50)'), a WRONG/CORRECT parameter table, PRR signal thresholds, and a full report template. It falls short of anchor 5 only because no complete example tool invocation or Python snippet is shown despite the 'COMPUTE, DON'T DESCRIBE' mandate.

Workflow Clarity

Phases 0-4 are clearly sequenced, each with an objective, numbered workflow, and explicit decision logic ('AOP found / No direct AOP match / Multiple AOPs'), and fallback chains provide error recovery with an 'INSUFFICIENT DATA' outcome tier. Checkpoints and feedback loops are explicit rather than implicit, matching the anchor-5 example's validate-and-recover structure; operations are read-only so the destructive/batch cap does not apply.

Progressive Disclosure

No bundle files exist, so the skill is entirely self-contained; the ~310-line body has clear section headers, separators, and an ASCII workflow map making it easy to navigate. Structure is good, but tool API details and the report template could arguably live in separate reference files, keeping it below the well-signaled one-level-deep-references anchor 5.

Specificity

The description names several specific capabilities — 'toxicity assessment via adverse outcome pathways (AOPs), real-world FAERS adverse event signals, FDA labels, and toxicogenomic associations' plus a concrete 'triangulates molecular initiating event to cellular outcome to organ-level toxicity to clinical adverse event' chain — but capabilities are framed as data sources rather than explicit action verbs, leaving minor gaps (e.g., report generation and risk classification only implied).

Completeness

It explicitly answers both what (assessment via four named evidence sources with a described triangulation method) and when ('Use for hepatotoxicity/cardiotoxicity/nephrotoxicity prediction and toxicology reports') with concrete trigger phrases. The 'when' is explicit and specific, clearly above the anchor-4 case where the 'when' could be more explicit.

Trigger Term Quality

Good natural keyword coverage: 'hepatotoxicity/cardiotoxicity/nephrotoxicity prediction', 'toxicology reports', 'adverse event signals', 'FDA labels' — phrases a domain user would naturally say. A few common synonyms are missing, notably 'side effects', 'drug safety', and 'ADR', keeping it below comprehensive anchor-5 coverage.

Distinctiveness Conflict Risk

The AOP/FAERS/FDA-label/toxicogenomics triangulation defines a clear niche with distinct organ-toxicity trigger terms, making conflict with other skills unlikely. It is not merely 'mostly distinct' (anchor 4) — the evidence-source combination and triggers are uniquely identifying.